SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy’s Lab rises on plan to expand capacity of three manufacturing plants in Telangana

06 Feb 2015 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 3093.60, up by 16.45 points or 0.53% from its previous closing of Rs. 3077.15 on the BSE.

The scrip opened at Rs. 3080.00 and has touched a high and low of Rs. 3114.85 and Rs. 3080.00 respectively. So far 13059 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3662.00 on 01-Dec-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 3370.00 and Rs. 3065.00 respectively. The current market cap of the company is Rs. 52602.19 crore.

The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 44.1% and 12.91% respectively.

Dr Reddy’s Laboratories is planning to invest Rs 82 crore to expand the capacity of three of its bulk drugs and intermediates manufacturing plants located in Telangana. In this regard, the company has approached the Ministry of Environment and Forests for necessary approvals for expanding the combined capacity of three facilities to over 142 tonnes per month from existing 41 tonnes.

Dr Reddy's Laboratories, Chemical Techops-II has proposed for expansion of bulk drugs and intermediates manufacturing unit (from 21.9 TPM to 68.76 TPM) in Telangana’s Medak district.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1236.50 1.10 (0.09%)
20-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1236.50
Cipla 1234.30
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×